Oral daily ibandronate: An effective and convenient therapy for skeletal complications in metastatic breast cancer

European Journal of Cancer, Supplement

Volumn 2, Issue 5, 2004, Pages 17-20

  Tripathy, D ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; IBANDRONIC ACID;

ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CARCINOMA; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; EVALUATION; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 2442570160     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.01.005     Document Type: Article

References (22)

1. Pickering L.M., Mansi J.L. The role of bisphosphonates in breast cancer management Review article. Curr. Med. Res. Opin. 18:2002;284-295
2. Body J.J. Metastatic bone disease clinical and therapeutic aspects. Bone. 13:(Suppl. 1):1992;S57-S62
3. Coleman R.E. Skeletal complications of malignancy. Cancer. 80:(Suppl. 8):1997;1588-1594
4. Pavlakis N., Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. 1:2002;CD003474
5. Koerberle D., Bacchus L., Thuerlimann B., Senn H.J. Pamidronate treatment in patients with malignant osteolytic bone disease and pain a prospective randomized double-blind trial. Support Care Cancer. 7:1999;21-27
6. Conte P.F., Latreille J., Mauriac L., et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate results from a multinational randomised controlled trial. J. Clin. Oncol. 14:1996;2552-2559
7. Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 335:1996;1785-1791
8. Hortobagyi G.N., Theriault R.L., Lipton A., et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16:1998;2038-2044
9. Theriault S.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions a randomised, placebo-controlled trial. J. Clin. Oncol. 17:1999;846-854
10. Hillner B.E., Ingle J.N., Chelbowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 21:2003;4042-4057
11. Adami S., Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf. 14:1996;158-170
12. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma a phase III, double-blind, comparative trial. Cancer J. 7:2001;377-387
13. DesHarnais Castel L., Bajwa K., Markle J.P., et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer. 9:2001;545-551
14. Chang J.T., Green L., Beitz J. Renal failure with the use of zoledronic acid. N. Engl. J. Med. 349:2003;1676-1679
15. Mian M., Beghe F., Caprio A., Aloj R., Bertelli A. Tolerability and safety of clodronate therapy in bone diseases. Int. J. Clin. Pharmacol. Res. 11:1991;107-114
16. Powles T., Paterson S., Kanis J.A., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. 20:2002;3219-3224
17. Body paper, add journal and no for ESMO supplement.
18. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14:2003;1399-1405
19. Tripathy D., Body J.J., Diel I., Bergstrom B. for the Bondronat Study Group. Oral daily ibandronate efficacy in reducing skeletal complications in patients with metastatic bone disease from breast cancer. Proc. ASCO. 22:2003;46. (abstr 185)
20. Diel I.J. Ibandronate a well-tolerated intravenous and oral treatment for metastatic bone disease. EJC Supplements. 2:(5):2004;. this issue (doi: 10.1016/j.ejcsup.2004.01.004)
21. Body J.J., Kanis J., Diel I.J., Bergstrom B. Risk reductions in metastatic breast cancer multivariate Poisson regression analyses of oral and i.v. ibandronate. Proc. ASCO. 46:2003;46. (abstr 184)
22. Body J.J., Diel I., Tripathy D., Bergstrom B. Impact of ibandronate on bone pain in patients with metastatic bone disease from breast cancer. Support Care Cancer. 11:2003;395-396. (abstr A-34)